10-Q: Processa Pharma Reports Q2 Loss, Boosts Cash with Offerings

Processa Pharmaceuticals, Inc. reported an increased net loss for Q2 2025 but significantly strengthened its cash position through recent public offerings, extending its capital runway into Q1 2026 while facing ongoing going concern doubts and Nasdaq listing challenges.

Summary

• Processa Pharmaceuticals, Inc. reported a net loss of $3,933,918 for the three months ended June 30, 2025, compared to $3,010,326 for the same period in 2024.
• The net loss for the six months ended June 30, 2025, was $6,768,323, an increase from $5,736,707 for the six months ended June 30, 2024.
• Research and development expenses increased to $2,447,286 for the three months and $4,035,767 for the six months ended June 30, 2025, driven by increased clinical trial costs for NGC-Cap.
• General and administrative expenses rose to $1,503,497 for the three months and $2,762,006 for the six months ended June 30, 2025, primarily due to salary increases for C-suite executives and higher stock-based compensation.
• Cash and cash equivalents significantly increased to $6,936,620 at June 30, 2025, from $1,191,325 at December 31, 2024, largely due to financing activities.
• The company raised net proceeds of $4.4 million from a public offering on January 29, 2025, and $6.2 million from another public offering on June 18, 2025, totaling $10.6 million.
• Subsequent to the quarter, on August 4, 2025, the company secured an additional $1.3 million in gross proceeds from a Securities Purchase Agreement and $1.1 million from an ATM agreement.
• The company's accumulated deficit reached $93.9 million at June 30, 2025.
• The company granted Intact Therapeutics an exclusive option to license PCS12852, receiving a $20,000 standstill payment, with potential for a 3.5% equity interest in Intact, $2.5 million in payments, milestone payments, and a 12% royalty on net sales.
• The licensing agreement for NGC-Gem (PCS3117) with Ocuphire Pharma, Inc. was terminated on June 27, 2025.
• The deadline for a Phase 2B/3/pivotal clinical trial under the Yuhan Corporation license agreement was extended from 48 months to 108 months.
• The company is re-evaluating PCS499 for Primary Glomerular Diseases (PGDs) following FDA's acceptance of surrogate endpoints for nephrology diseases.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While the company successfully raised significant capital, extending its cash runway, and made some pipeline progress (PCS12852 option, Yuhan extension, PCS499 re-evaluation), these positives are overshadowed by increasing net losses, an explicit 'going concern' warning, and the immediate threat of Nasdaq delisting. The termination of the NGC-Gem license and ongoing legal issues also contribute to the negative outlook, indicating significant operational and financial challenges ahead despite the recent cash infusion.

Positives

• Significant increase in cash and cash equivalents to $6.9 million at June 30, 2025, from $1.2 million at December 31, 2024, providing a stronger liquidity position.
• Successful capital raises in January and June 2025, generating $10.6 million in net proceeds, and an additional $2.4 million in gross proceeds in August 2025, extending the capital runway into Q1 2026.
• Progress in the NGC-Cap Phase 2 advanced or metastatic breast cancer trial, with active site additions and patient enrollment, aiming for preliminary safety-efficacy data.
• Granting an exclusive option to Intact Therapeutics for PCS12852, a Phase 2B ready drug, which includes an upfront payment, potential equity interest, future payments, milestones, and a 12% royalty.
• Extension of the Yuhan Corporation license agreement deadline for a Phase 2B/3/pivotal clinical trial from 48 months to 108 months, providing more time for development.
• Re-evaluation of PCS499 for Primary Glomerular Diseases (PGDs) based on new FDA guidance, with data suggesting potential for improved safety and efficacy compared to existing treatments.

Negatives

• Increased net loss for both the three and six months ended June 30, 2025, compared to the prior year periods, indicating continued unprofitability.
• Accumulated deficit grew to $93.9 million at June 30, 2025, reflecting ongoing losses since inception.
• Substantial doubt exists about the company's ability to continue as a going concern within one year without additional funding.
• The company has not generated any product revenue to date and does not expect positive cash flow from operations in the foreseeable future.
• Risk of Nasdaq delisting due to the common stock bid price falling below the $1.00 minimum requirement, with a compliance deadline of August 4, 2025.
• Termination of the licensing agreement for NGC-Gem (PCS3117) with Ocuphire Pharma, Inc., removing a pipeline asset.
• Ongoing legal proceedings, including a lawsuit against Elion and a lawsuit by former investors, which could result in material adverse impacts and significant defense costs.
• Dilution of existing stockholders' ownership interest due to recent and potential future equity offerings.

Risks

• Limited cash and history of losses, with no assurance of achieving profitability.
• Inability to obtain adequate additional financing when needed, which could lead to delays, reductions in scope, or suspension of clinical trials and R&D programs.
• Failure to secure required FDA or other governmental approvals for product candidates.
• Impact of competitive or alternative products, technologies, and pricing on the market adoption of NGC therapies.
• Uncertainty regarding the success in developing and commercializing technology, including through licensing arrangements.
• Inadequacy of patent protections for intellectual property rights and the cost of maintaining, enforcing, and defending those patents.
• Exposure to and ability to defend against third-party claims and challenges to intellectual property rights.
• Risk of delisting from the Nasdaq Capital Market if the company fails to regain compliance with listing rules, which could limit investor transactions and access to future financing.
• Disruptions at the FDA and other government agencies, including funding cuts or staffing reductions, which could hinder product development and approval.
• Relinquishing valuable rights to product candidates, future revenue streams, or granting licenses on unfavorable terms if additional capital is raised through collaborations or licensing arrangements.
• Dilution of existing stockholders' ownership interest and potential adverse effects on stockholders' rights if additional capital is raised through public or private equity offerings.
• Subject to covenants limiting or restricting specific actions if additional capital is raised through debt financing.

Future Outlook

The company expects to continue to be dependent upon equity and/or debt financing until it can generate positive cash flows from operations, as none of its drug candidates have been approved for sale. Current funds, including recent August 2025 proceeds, are expected to satisfy capital needs into the first quarter of 2026. The company plans to raise additional funds through various means, including public or private equity offerings, debt financings, collaborations, and licensing arrangements, but only if terms are acceptable. It is exploring options to pursue a cryptocurrency treasury strategy. The company anticipates clinical trial costs for NGC-Cap will increase in 2025 compared to prior periods. Preliminary safety-efficacy data from the NGC-Cap Phase 2 breast cancer trial is expected to provide insight and potentially help adaptively modify the protocol.

Management Comments

• We are exploring options to pursue a cryptocurrency treasury strategy.
• We plan to obtain preliminary safety-efficacy data from these breast cancer patients in order to provide insight into the benefit of NGC-Cap over existing treatments.
• This preliminary data should provide information that could also help to adaptively modify the protocol to increase the efficiency and/or improve the information obtained from the study.
• The data suggests that PCS499 may not only be safer, but also more efficacious in more patients than PTX or other drugs presently used onand off-label for PGDs.
• We plan to use the net proceeds from both financings for continued research and development for NCG-Cap, and for working capital and general corporate purposes.
• We plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable to us.

Industry Context

Processa Pharmaceuticals operates in the highly capital-intensive clinical-stage biopharmaceutical sector, focusing on Next Generation Cancer therapy (NGC) drugs. The strategy of modifying existing FDA-approved oncology drugs to improve safety and efficacy is a common approach to de-risk drug development. The company's re-evaluation of PCS499 for Primary Glomerular Diseases (PGDs) aligns with industry trends where regulatory changes, such as the FDA accepting surrogate endpoints, can open new therapeutic avenues for existing compounds. The termination of the NGC-Gem license and the pursuit of out-licensing for non-oncology drugs like PCS12852 and PCS499 reflect a strategic focus on core oncology assets and a common practice in the industry to monetize non-core assets or share development risks. The reliance on equity financing and the 'going concern' warning are typical for clinical-stage biotechs that have not yet brought a product to market.

Comparison to Industry Standards

• As a clinical-stage biopharmaceutical company, Processa Pharmaceuticals' lack of product revenue and ongoing net losses are standard for the industry, where significant R&D investment precedes potential commercialization.
• The company's cash runway into Q1 2026, even after significant capital raises, is relatively short compared to more established biopharma companies, highlighting the urgent need for further financing typical of smaller, early-stage firms.
• The increase in R&D expenses for NGC-Cap's Phase 2 trial is consistent with the progression of clinical programs, which typically become more costly in later stages.
• The licensing option for PCS12852 with Intact Therapeutics, including potential equity, milestone payments, and royalties, is a common industry model for non-dilutive funding and risk-sharing for pipeline assets.
• The Nasdaq minimum bid price deficiency is a common challenge for smaller, publicly traded biotechs, often reflecting market skepticism about their long-term viability without approved products or significant partnerships.
• The termination of the NGC-Gem license is not uncommon in drug development, as companies frequently re-evaluate pipeline assets based on strategic fit, clinical data, or financial considerations.

Legal Proceedings

• On May 7, 2024, the company received notification from Elion purporting to terminate a license agreement due to alleged breach. The company disputes the claim and filed a complaint on July 5, 2024, seeking monetary damages, declaratory judgment, and injunctive relief. Discovery has commenced.
• On December 3, 2024, Jason Assad and Marc Gyimesi, investors, filed a lawsuit alleging fraud and negligent misrepresentation related to a February 2021 private offering. The company filed a motion to dismiss the complaint on April 25, 2025, which is awaiting decision. Discovery has commenced.

Related Party Transactions

• CorLyst, LLC (CorLyst) reimburses the company for shared costs related to payroll, health insurance, and rent, recognized as a reduction of general and administrative operating expenses. Reimbursements were approximately $31,000 for the three months and $60,000 for the six months ended June 30, 2025.
• At June 30, 2025, approximately $29,000 was due from CorLyst as a current asset.
• The company's President, Research and Development, is the CEO of CorLyst, and CorLyst is a stockholder.

Stakeholder Impact

• **Shareholders:** Significant dilution from recent and potential future equity raises. Risk of further dilution if warrants are exercised. Nasdaq delisting risk could reduce liquidity and market quotations for shares. Going concern doubt poses a fundamental risk to investment value.
• **Employees:** Stock-based compensation is a component of their remuneration. Voluntary departures of R&D employees noted in 2024. Future funding issues could impact employment stability.
• **Customers (future):** Potential for improved safety and efficacy profiles of NGC drugs could benefit cancer patients if approved. Termination of NGC-Gem means one less potential treatment option.
• **Suppliers/CROs:** Contractual obligations with CROs for future services total up to $13.1 million, indicating continued engagement. However, funding constraints could impact these relationships.
• **Creditors:** The 'going concern' warning indicates increased risk for creditors, as the company's ability to meet obligations depends on future financing.

Next Steps

• Obtain preliminary safety-efficacy data from the NGC-Cap Phase 2 breast cancer trial to inform future protocol modifications.
• Finalize the license agreement with Intact Therapeutics for PCS12852 within the 120-day (or extended) due diligence period.
• Continue to seek additional funding through equity/debt financing, collaborations, strategic alliances, or licensing arrangements.
• Address the Nasdaq minimum bid price deficiency to regain compliance and avoid delisting.
• Vigorously defend against the ongoing legal proceedings with Elion and the former investors.
• Continue re-evaluating PCS499 for Primary Glomerular Diseases (PGDs).

Key Dates

Recommendation

Despite recent capital raises that have temporarily bolstered cash, the company's fundamental financial position remains precarious, evidenced by increasing net losses and an explicit 'going concern' warning. The immediate threat of Nasdaq delisting adds significant uncertainty and could severely impair liquidity and future financing capabilities. While there is some pipeline progress, it is early-stage and highly speculative. The termination of a key licensing agreement and ongoing legal disputes further compound the risks. A seasoned investor would recognize the high risk of capital impairment due to operational burn, dilution, and regulatory/listing challenges, making a 'sell' or 'strong sell' recommendation appropriate for existing holders, and advising against new positions.

Keywords

Biopharmaceutical, Cancer Therapy, Oncology, Clinical Stage, SEC Filing, 10-Q, Financial Results, Capital Raise, Public Offering, Nasdaq Listing, Going Concern, Drug Development, NGC-Cap, PCS12852, PCS499, Diabetic Gastroparesis, Primary Glomerular Diseases, Warrants, Stock Dilution, Research and Development, Liquidity, Legal Proceedings